Jonathan Todd, Vice Chair of Benesch’s Transportation & Logistics Practice Group, was quoted in MedCity News discussing the legal and policy implications of the Trump administration’s proposed pharmaceutical tariffs.
Todd addressed the growing tension between new tariff plans and longstanding trade agreements like the WTO Pharma Agreement, noting the evolving legal framework under which the administration is operating.
“Many of the actions of this Trump administration are continuations of the Trump 45 administration,” Todd said. “There’s much more activity now and the policy objectives are much more ambitious. But the trend line is similar to eight years ago.”
He also pointed to the Department of Commerce’s ongoing Section 232 investigation as a key mechanism for advancing the administration’s America-first trade strategy.
Read the full article here.